Clinical Trial Update: Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of H3B-6545 in Japanese women with estrogen receptor–positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• H3B-6545

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED